US Stock MarketDetailed Quotes
ORKA Oruka Therapeutics
- 22.235
- +0.915+4.29%
Trading Dec 13 15:35 ET
778.19MMarket Cap-58.51P/E (TTM)
22.640High21.060Low212.24KVolume21.110Open21.320Pre Close4.64MTurnover0.91%Turnover RatioLossP/E (Static)35.00MShares33.00052wk High2.29P/B520.42MFloat Cap10.06852wk Low--Dividend TTM23.41MShs Float40838092.445Historical High--Div YieldTTM7.41%Amplitude10.068Historical Low21.864Avg Price1Lot Size
Oruka Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | |
|---|---|---|
| Total revenue | 0 | 0 |
| Operating revenue | --0 | --0 |
| Cost of revenue | ||
| Gross profit | ||
| Operating expense | 29.45M | 21.49M |
| Selling and administrative expenses | --3.76M | --2.82M |
| -General and administrative expense | --3.76M | --2.82M |
| Research and development costs | --25.69M | --18.67M |
| Operating profit | -29.45M | -21.49M |
| Net non-operating interest income expense | 826K | -750K |
| Non-operating interest income | --1.33M | ---- |
| Non-operating interest expense | --504K | --750K |
| Other net income (expense) | ||
| Income before tax | -28.62M | -22.24M |
| Income tax | ||
| Net income | -28.62M | -22.24M |
| Net income continuous Operations | ---28.62M | ---22.24M |
| Minority interest income | ||
| Net income attributable to the parent company | -28.62M | -22.24M |
| Preferred stock dividends | ||
| Other preferred stock dividends | ||
| Net income attributable to common stockholders | -28.62M | -22.24M |
| Basic earnings per share | -1.46 | -0.7566 |
| Diluted earnings per share | -1.46 | -0.7566 |
| Dividend per share | ||
| Currency Unit | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP |
Heat List
US
Overall
Symbol
Price
% Chg
No Data